KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Other Non-Current Liabilities (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $171000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $171000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $171000.0, a N/A change, with the full-year FY2025 number at $171000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities was $171000.0 for Q4 2025 at Biolife Solutions, down from $363000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.5 million in Q3 2021 to a low of $42000.0 in Q4 2021.
  • A 4-year average of $2.1 million and a median of $2.1 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 5419.05% in 2022, then plummeted 88.62% in 2023.
  • Biolife Solutions' Other Non-Current Liabilities stood at $42000.0 in 2021, then soared by 5419.05% to $2.3 million in 2022, then plummeted by 84.34% to $363000.0 in 2023, then plummeted by 52.89% to $171000.0 in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Other Non-Current Liabilities are $171000.0 (Q4 2025), $363000.0 (Q3 2023), and $2.3 million (Q4 2022).